Sun Pharmaceutical (SUNPHARMA) — Financial Results

Sun Pharmaceutical reported Q3 FY26 consolidated sales of ₹1,54,691 million, up 15.1% YoY, with EBITDA of ₹49,485 million (23.4% growth) and net profit of ₹33,688 million (16% growth). EBITDA margin improved to 31.9%. The company maintains market leadership in India (8.4% share) and launched key products including Unloxcyt and Ilumya in the US. An interim dividend of ₹11 per share was declared. Management confirmed disciplined M&A strategy focused on emerging markets and innovative medicines, with 116 pending ANDAs and expected US generics recovery following manufacturing compliance.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SUNPHARMA ✨ Ask AI About This

About Sun Pharmaceutical Industries Limited (SUNPHARMA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹4,50,643.09 Cr P/E: 41.3 ROE: 15.1% ROCE: 20.3%

View full SUNPHARMA stock details →

📡 Get AI alerts when SUNPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUNPHARMA — Free

💡 Ask AI about this filing

"How does this financial results affect Sun Pharmaceutical Industries Limited's outlook?" "What did Sun Pharmaceutical Industries Limited announce on 4 February 2026?" "Is this positive or negative for SUNPHARMA?"

Ask AI Free →

📊 More SUNPHARMA filings

See all SUNPHARMA filings →

🔥 Also filed on 4 February 2026

SBICARD SBI Cards and Payment Services Limited Financial Results TATASTEEL Tata Steel Limited Announcement TATAPOWER Tata Power Company Limited Financial Results TATAPOWER Tata Power Company Limited Financial Results TATAPOWER Tata Power Company Limited Financial Results TRENT Trent Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUNPHARMA files new disclosures

Track SUNPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.